Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones

Community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality worldwide. The treatment of CAP has been complicated by several factors, including the expanding spectrum of causative organisms and the rising prevalence of antibiotic resistance among respiratory pathogens. Initial...

Full description

Saved in:
Bibliographic Details
Published inClinical microbiology and infection Vol. 12; no. s3; pp. 2 - 11
Main Authors Carratalá, J., Martín-Herrero, J.E., Mykietiuk, A., García-Rey, C.
Format Journal Article
LanguageEnglish
Published Oxford, UK Elsevier Ltd 01.05.2006
Blackwell Publishing Ltd
Subjects
Adult
Anti-Bacterial Agents - therapeutic use
Clinical Trials as Topic
Community-Acquired Infections - drug therapy
Community-Acquired Infections - microbiology
Community-acquired pneumonia
Drug Resistance, Bacterial
Haemophilus influenzae
Humans
Legionella
Levofloxacin
mortality
Ofloxacin - therapeutic use
Pneumonia, Pneumococcal - drug therapy
Pneumonia, Pneumococcal - microbiology
review
Streptococcus pneumoniae
Streptococcus pneumoniae - growth & development
mortality
Community-acquired pneumonia
legionella
levofloxacin
review
Streptococcus pneumoniae
Online AccessGet full text

Cover

More Information
Summary:Community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality worldwide. The treatment of CAP has been complicated by several factors, including the expanding spectrum of causative organisms and the rising prevalence of antibiotic resistance among respiratory pathogens. Initial antimicrobial treatment for patients with CAP is usually selected empirically and should provide appropriate coverage against the most common causative organisms, including resistant strains. Respiratory fluoroquinolones, such as levofloxacin, are the only antimicrobials that are highly active against the pathogens most frequently implicated in CAP, including macrolide-resistant and penicillin-resistant pneumococci, Haemophilus influenzae, Legionella spp., and atypical agents. This paper reviews recent studies involving adult patients with CAP that suggest that levofloxacin, as compared with other conventional antibiotic treatments, may be associated with better clinical outcomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-3
ObjectType-Review-1
ISSN:1198-743X
1469-0691
DOI:10.1111/j.1469-0691.2006.01392.x